DOSSIER · 13F-HR · Q2 2026

TRV GP V, LLC

$498M in tracked AUM across 3 positions as of Q2 2026.

TG
CIK 0001990717 · last filed Jun 30, 2026
Total AUM
$498M
as of Q2 2026
Holdings
3
positions
Whale Score
71
71
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

The filing for TRV GP V, LLC reveals a highly specialized and concentrated investment portfolio with a total market value of $328.83 million as of September 30, 2025. This represents a substantial increase in portfolio value of 98.5% compared to the previous quarter's value of $165.65 million. The portfolio is characterized by extreme concentration, consisting of only two equity holdings. This lack of diversification suggests a high-conviction, high-risk investment strate...

Key Holdings

The portfolio is dominated entirely by two positions: Rapport Therapeutics, Inc. and Septerna, Inc.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
RAPP
RAPPORT THERAPEUTICS, INC.
$262M6.3M52.5%
02
SEPN
SEPTERNA, INC.
$208M6.2M41.8%
03
MAZE
MAZE THERAPEUTICS, INC.
$28M951K5.7%

Filing history

2026Q2Jun 30
$498M 24.2%
3 positionsView →
2026Q1Mar 31
$401M 6.6%
3 positionsView →
2025Q4Dec 31
$429M 30.5%
3 positionsView →
2025Q3Sep 30
$329M 98.5%
2 positionsView →
2025Q2Jun 30
$166M 44.5%
4 positionsLocked
2025Q1Mar 31
$115M 61.0%
3 positionsLocked
2024Q4Dec 31
$294M
3 positionsLocked